Juvaris BioTherapeutics and SomaGenics, Invitrogen and Agile Software, Genta, and Qiagen | GenomeWeb

Juvaris, SomaGenics Ink Product Development Deal

Juvaris BioTherapeutics has formed a collaboration to develop products combining its immunomodulatory and vaccine technologies with SomaGenics’ RNA-based gene inhibition technology, the companies said this week.

The companies said that the initial focus of the alliance will be on a novel immune stimulant and specific gene inhibitor combination that could be used to elicit non-specific and specific protection against anthrax and anthrax toxin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.